f African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed efficacy similar to that of DB829 in dose-response studies in mouse models of first-and second-stage African sleeping sickness. The in vitro time to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010 than for DB829. No cross-resistance was observed between 28DAP010 and pentamidine on the tested Trypanosoma brucei gambiense isolates from melarsoprol-refractory patients. 28DAP010 is the second promising preclinical candidate among the diamidines for the treatment of second-stage African sleeping sickness.
A frican sleeping sickness, also known as human African trypanosomiasis (HAT), is a tropical disease that threatens millions of people living in sub-Saharan Africa (1) . It is caused by two subspecies of the single-celled parasite Trypanosoma brucei, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense. The protozoans are transmitted by the bite of infected tsetse flies. The disease is fatal without effective treatment. The burden of the disease has been reduced to some extent by increased control interventions, but the disease is still one of the most neglected tropical diseases, and it is estimated by the WHO that there are still 25,000 to 30,000 infected patients (2, 3) .
HAT progresses in two stages. In the first stage, the parasites reside in the blood and the lymphatic system. In the second stage, the parasites cross the blood-brain barrier (BBB) and spread the infection to the central nervous system (CNS), leading to neurological and psychiatric disorders, including irregular and fragmented sleeping patterns, behavioral changes, motor weakness, coma, and ultimately death (4) .
Patients can be cured only by effective and safe drugs. Vaccines are not available and are unlikely to be developed in the near future, and self-healing through the body's own immune system is also not possible due to antigenic variation of the surface glycoproteins of the parasites (5) . The drugs currently available have serious disadvantages such as adverse effects, limited efficacy, complicated treatment schedules, and the need for parenteral administration. New drugs are therefore needed, especially for the second stage of the disease.
In the search for new drugs, aromatic diamidines are seen as promising candidates for use against HAT. These compounds are known to have a broad spectrum of antiprotozoal activities (6) . Pentamidine has been in use since the 1940s for first-stage T. b. gambiense HAT and against leishmaniasis and Pneumocystis jirovecii pneumonia (7) . Diminazene (8) and isometamidium (a monoamidine) are used to treat animal trypanosomiasis. Therefore, considerable effort has been put into the synthesis and investigation of novel aromatic diamidines with improved properties for use against HAT.
One problem with diamidines is that they are protonated at physiological pH and therefore do not easily cross the gastrointestinal tract and the BBB by diffusion. Their cationic nature was therefore believed to reduce their potential for use as oral drugs and to reduce their efficacy against second-stage HAT by any route of administration; therefore, much effort went into the design of prodrugs (6, 9) . Prodrugs are inactive against trypanosomes in vitro but can be metabolized to the active diamidine molecules by host enzymes upon administration in vivo (10) (11) (12) , thus serving as potentially orally active drugs. The prodrug approach worked well with regard to oral bioavailability in animal models (9, 13, 14) as well as in humans, in whom the prodrug DB289 (pafuramidine maleate) underwent clinical trials as the first oral drug for treatment of first-stage HAT patients (15, 16) . Several other prodrugs have been tested in the second-stage mouse model, but few of them were able to cure CNS infections in mice (14, 17) .
During a series of tests in our laboratory, we discovered that the diamidine DB829 was intrinsically active in second-stage animal models (14, 18) . This was unexpected, as simple diamidines (amidines without substituents on either nitrogen atom) are thought to be unable to cross the BBB by diffusion due to their cationic nature. For many years, DB829 remained the only diamidine that showed high CNS activity in vivo (14, 19) .
Recently, we found that 28DAP010 (also known as CPD0905) and its close analogues 19DAP025 and 27DAP060 were highly active in vitro against T. b. rhodesiense and were curative in the stringent T. b. rhodesiense STIB900 first-stage mouse model at the low dose of 4 ϫ 5 mg/kg of body weight (i.e., daily dose of 5 mg/kg given on 4 consecutive days) or as a single dose of 10 mg/kg by an intraperitoneal (i.p.) route of administration (20) . In this paper, we present more data from our investigations of this new novel diamidine with high CNS activity in vivo, 28DAP010, and its analogues 19DAP025 and 27DAP060. We performed a full doseresponse experiment in the STIB900 acute-stage mouse model to determine the minimal curative dose for the three compounds and evaluated their CNS activity in the GVR35 CNS mouse model. As 28DAP010 showed better efficacy than the analogues, we carried out a detailed biological characterization of this compound. We collected in vitro data on different T. brucei strains and subspecies, with a particular emphasis on trypanocidal activity on T. b. gambiense, as the majority (Ͼ98%) of African sleeping sickness patients are infected with T. b. gambiense (2) . Additionally, we assessed the time to kill of 28DAP010 in vitro using microcalorimetry, a new method to measure drug activity on a real-time basis (21) . This was important, because aromatic diamidines typically kill the trypanosomes rather slowly, with a time to kill of about 24 to 48 h after treatment (22) . Among the diamidines, DB829 was one of the slowest-acting compounds, with a time to kill of Ͼ48 h (23). After having analyzed the pharmacokinetic properties of 28DAP010 in mice at a curative single dose, we assessed the parasite clearance time at an identical dose in mice infected with T. b. rhodesiense and T. b. gambiense strains.
MATERIALS AND METHODS

Materials.
Pentamidine isethionate was purchased from Sigma-Aldrich (St. Louis, MO). Syntheses of 28DAP010 (CPD-0905) (20) , 19DAP025 (20) , 27DAP060 (20) , DB829 (24) , DB1244 (20) and deuterium-labeled DB75 (DB75-d8; deuterated phenyl rings; internal standard) (25) , all isolated as their hydrochloride salts, have been previously reported.
Antitrypanosomal activities of 28DAP010 and pentamidine in vitro. (i) Preparation of compounds. Compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and finally diluted in culture medium prior to the in vitro assay. The DMSO concentration never exceeded 1% in the in vitro alamarBlue assays at the highest drug concentration. For microcalorimetry assays, the DMSO concentration was kept at 0.1% in all samples.
(ii) Parasites. The T. brucei strains used in this study are described in Table 1 .
(iii) In vitro growth inhibition assays using T. brucei subspecies. The 50% inhibitory concentrations (IC 50 s) were determined using the alamarBlue assay as described by Räz et al. (26) , with a 3-day drug exposure and minor modifications as described previously (23) . Assays were carried out at least three times independently and each time in duplicate. The IC 50 s are the means of the independent assays. Coefficients of variation were less than 50%. Different culture and assay media were used for T. b. gambiense and T. b. rhodesiense, as previously described by Wenzler et al. (23) .
(iv) Microcalorimetry studies using T. brucei subspecies. In vitro time of drug action was monitored using isothermal microcalorimetry. With this method, the time of drug action on a parasite population can be determined on a real-time basis (21, 23) . The strain STIB900 was used as a representative for T. b. rhodesiense and STIB930 (and sometimes additionally ITMAP141267) for T. b. gambiense.
For experiments with continuous drug exposure, bloodstream trypanosomes (2 ml at 5 ϫ 10 4 /ml per ampoule) were spiked with different concentrations of 28DAP010, with a final DMSO concentration of 0.1% (vol/vol). Negative controls contained culture medium only. The heat flow was continuously measured (1 reading/second) at 37°C in the isothermal microcalorimetry instrument (thermal activity monitor, model 249 TAM III). Each experiment with continuous drug exposure was set up in triplicate and carried out a total of 3 times (21).
(v) Inoculum studies. For studies of the drug effect on different parasite densities in the inoculum, the parasite density was reduced to 1 ϫ 10 4 /ml of bloodstream trypanosomes and supplemented with 28DAP010 at the desired concentrations. Inhibition of growth and viability was compared with that in the samples containing the standard inoculum of 5 ϫ 10 4 /ml of bloodstream trypanosomes and the same drug concentrations (23) . Each experiment was set up in triplicate and repeated once.
(vi) Drug wash-out experiments. For the 24-h exposure experiment, trypanosomes (T. b. rhodesiense strain STIB900 and T. b. gambiense strain STIB930) were incubated with 28DAP010 for 24 h at 37°C and then washed twice to remove the compound. Subsequently, the washed trypanosomes were resuspended in drug-free culture medium, transferred to ampoules, and inserted into the isothermal microcalorimetry instrument. The drug-free control samples (drug free, wash-out) were washed identically to the drug-containing samples. Each 24-h exposure experiment was set up in triplicate and repeated once (23) .
(vii) Analysis of microcalorimetry heat flow data. To facilitate further calculations, the recorded data were resampled to obtain an effective sampling frequency of 1 data point per 1.5 min, using the manufacturer's software (TAM assistant version v1.2.4.0), and exported to a spreadsheet. Forty-five minutes was added to the time data to account for the preparation of the ampoules and the transfer from the bench to the calorimeter. Resulting data were plotted as heat flow (in W) over time. Each single curve for heat flow (in watts) over time was analyzed using the R statistical package (27) . Data were smoothed using a cubic spline (smooth.spline function) in the R statistical software (27) (28) (29) (30) . The time to onset of drug action was determined as the time at which a divergence between the heat flow of the drug-free controls and the drug-containing specimens could be observed. The time to peak was determined as the time point at which the highest heat flow was measured for each samples. The time to kill the parasite population was defined as the time point when the heat production was reduced to the level of the sterile medium control (base level) (23) .The growth rate () of each culture was calculated using the heatover-time data (integrated heat flow data over time). For this calculation, the Gompertz growth model was fitted over the whole curve using R software and the Grofit package as described previously (23, 31) . The growth rate calculated based on the heat released by the metabolic activity in the culture is considered only as a proxy for the growth rate calculated from the exponential growth phase by conventional approaches, since lysis and chemical processes due to the nature of the medium might also contribute to the overall heat signal (23, 31) . In vivo studies. (i) Efficacy and time to kill in mice. The efficacy and time-to-kill experiments were performed at the Swiss Tropical and Public Health Institute. Adult female NMRI (Naval Medical Research Institute) mice were obtained from Janvier, France, or from Harlan, the Netherlands. They weighed between 20 and 25 g at the beginning of the study and were housed under standard conditions with food pellets and water ad libitum. All protocols and procedures were reviewed and approved by the veterinary authorities of Canton Basel-Stadt, Switzerland. For experiments with mice, the compounds were dissolved in DMSO and further diluted with distilled water to a final DMSO concentration of 10% prior to administration to the animals.
(ii) Efficacy in an acute-stage T. b. rhodesiense STIB900 mouse model. The STIB900 acute-stage mouse model mimics the first (hemolymphatic) stage of HAT. Experiments were performed as previously reported (23) . Briefly, four female NMRI mice per group were infected intraperitoneally (i.p.) with 5 ϫ 10 3 STIB900 bloodstream forms. Drug administration (i.p.) began 3 days after infection. A control group was infected but remained untreated. All mice were monitored for parasitemia by microscopic examination of tail blood twice a week until day 30, followed by once a week until 60 days after infection. The time to parasite relapse was recorded to calculate the mean relapse time in days after infection. Mice were euthanized after parasitemia relapse detection. Mice were considered cured if they survived and were aparasitemic until day 60.
(iii) Efficacy in acute-stage T. b. gambiense mouse models. Experiments were performed as previously reported (23) . Briefly, four female NMRI mice per group were immunosuppressed with 200 mg/kg of cyclophosphamide (Endoxan, Baxter, Deerfield, IL) 2 days prior to infection with 10 5 bloodstream forms with one of the four T. b. gambiense strains (i.e., ITMAP141267, STIB930, 130R, or 45R). Immunosuppression with cyclophosphamide followed every second week until the end of the experiment. Drug administration (i.p.) began 3 days after infection. A control group was infected but remained untreated. Mice were monitored for parasitemia twice a week until day 30 and then once a week until 90 days after infection. Mice were considered cured if they survived and were aparasitemic until day 90.
(iv) Efficacy in a CNS stage T. b. brucei GVR35 mouse model. The GVR35 mouse CNS model mimics the second stage of the disease. GVR35 is a less virulent strain than STIB900 and crosses the BBB of mice around 7 days after infection (32) . Experiments were performed as previously reported (14) , with minor modifications. Five female NMRI mice per experimental group were used. Each mouse was inoculated i.p. with 2 ϫ 10 4 bloodstream forms. The drug administration was i.p. for diamidines and per os (p.o.) for prodrugs on five consecutive days from day 17 to 21 after infection. Some experimental groups were treated for 10 consecutive days (day 17 to 26 after infection). A negative-control group was treated on day 17 with a single dose of diminazene aceturate at 40 mg/kg of body weight i.p., which is subcurative since it clears the trypanosomes only from the hemolymphatic system and not from the CNS, leading to a subsequent reappearance of trypanosomes in the blood (33) . Parasitemia was monitored twice a week from the time after treatment until day 50 after infection, followed by once a week until 180 days after infection. Mice were considered cured when there was no parasitemia relapse detected over the 180-day observation period. Surviving and aparasitemic mice were euthanized on day 180.
(v) In vivo time to kill. Infection with T. b. rhodesiense and T. b. gambiense and immunosuppression for T. b. gambiense-infected mice were carried out as described for the efficacy experiments. In different mouse models the parasite load varied, an observation that was also made in the efficacy experiments. Mice were treated with a single dose of 20 mg/kg i.p. 3 days postinfection. The first microscopic examination of blood was done 24 h after treatment, and examination was done subsequently twice per day until all parasites had disappeared. When microscopy was not sensitive enough to detect any parasites, a hematocrit buffy coat examination was performed. The first time point at which no trypanosomes were detected on the microscopic slide or in the buffy coat was considered the clearance time (or time to kill) in mice. The detection limit by buffy coat examination was Ͻ100 trypanosomes/ml of blood. Mice were kept and further observed by tail blood examination until the end of the experiment to verify whether the administered dose was curative in the infected mice (23) .
Pharmacokinetic studies. (i) Animals for PK studies. The pharmacokinetic (PK) studies were performed at the University of Kansas. Protocols for the animal studies were approved by the Institutional Animal Care and Use Committee of the University of Kansas. Male Swiss Webster mice (weighing 20 to 25 g) were purchased from the Charles River Laboratories (O'Fallon, MO). Mice were housed in a clean room under filtered, pathogen-free air, in a 12-h light/dark cycle, and with food pellets and water available ad libitum. Although a different strain and sex of mice were used in our PK studies compared to efficacy studies, we did not expect that diamidine PK would differ significantly between different strain and sex of mice.
(ii) Pharmacokinetics and brain exposure in mice. The single-dose pharmacokinetics of 28DAP010 was evaluated in mice (in triplicate) after intravenous (i.v.) and i.p. administration. 28DAP010 was dissolved in sterile saline. The doses were 7.5 mol/kg (approximately 2.4 mg/kg) for i.v. administration and 65 mol/kg (approximately 21 mg/kg) for i.p. administration, which was the dose used in the in vivo time-to-kill study. The dose volume was 5 ml/kg. No overt adverse effects were observed in mice at these dose levels. Blood sampling occurred at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h postdose. Additional earlier sampling times, at 0.0167 and 0.083 h, were included for the i.v. administration. Blood was collected via the submandibular vein (ϳ0.04 ml per bleed) or heart (ϳ0.8 ml) into lithium heparin-coated Microvette tubes (Sarstedt Inc., Newton, NC). Terminal blood and brain samples were collected at 4, 12, and 72 h postdose. Plasma was obtained by centrifugation. Excised mouse brain samples were quickly rinsed with distilled water, blotted dry with tissue paper, and weighed. All samples were stored at Ϫ20°C until further processing for quantification by ultrahigh-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS).
(iii) Plasma and tissue binding assays. Binding of 28DAP010 to mouse plasma and brain was evaluated by the equilibrium dialysis method using a rapid equilibrium dialysis device (Thermo Scientific Pierce, Rockford, IL) as previously described (34) . Briefly, blank (untreated and uninfected) mouse brains were collected and homogenized in 2 volumes (vol/ wt) of water (3-fold dilution). 28DAP010 was spiked into blank plasma or brain homogenates to yield a final drug concentration of 1 M. Spiked plasma or brain homogenates (in triplicate) were added to the dialysis device and dialyzed against phosphate-buffered saline (PBS) for 6 h at 37°C to reach equilibrium between the plasma/tissue compartment and the buffer compartment. At the end of incubation, samples from the plasma/tissue compartment and the buffer compartment were collected and analyzed for total and unbound concentrations by UPLC-MS/MS. Unbound fractions in the mouse brain (f u, brain ) were calculated by correcting for dilution (35) .
(iv) UPLC-MS/MS analysis. (a) Sample preparation. Plasma samples (2 l) were mixed with 200 l of 7:1 (vol/vol) methanol-water containing 0.1% trifluoroacetic acid and an internal standard (1 nM DB75-d8) and then vortex mixed for 30 s, followed by centrifugation (2,800 ϫ g) to pellet proteins. The supernatant was transferred to a new tube and dried using a 96-well microplate evaporator (Apricot Designs Inc., Covina, CA) under N 2 at 50°C and reconstituted with 100 l of 15% methanol containing 0.1% trifluoroacetic acid.
(b) Determination of drug concentration. The reconstituted samples (5-l injection volume) were analyzed for drug concentration using a Waters Xevo TQ-S mass spectrometer (Foster City, CA) coupled with a Waters Acquity UPLC I-Class system. Compounds were separated on a Waters UPLC BEH C 18 column (2.1 mm by 50 mm by 1.7 m) equilibrated at 50°C. UPLC mobile phases consisted of water containing 0.1% formic acid (solution A) and methanol containing 0.1% formic acid (solution B). After a 0.15-min initial holding period at 10% solution B, mobile phase composition started with 10% solution B and was increased to 80% solution B over 2.2 min with a flow rate of 0.4 ml/min. Then the column was washed with 90% solution B for 0.5 min and was reequilibrated with 5% solution B for 1.1 min before injection of the next sample. The characteristic single reaction monitoring (SRM) transition for 28DAP010 and DB75-d8 were m/z 317.1¡283.1 and 313.2¡296.3, respectively, under positive electrospray ionization mode. The calibration curves for 28DAP010 ranged from 0.5 nM to 50 M. The intraday coefficient of variation (CV) and accuracy were determined by measuring the same preparation of three standards three times on the same day. At concentrations of 5, 1,000, and 25,000 nM, the intraday CV and average accuracy of 28DAP010 quantification were 11.2% and 103%, 5.33% and 104%, and 0.70% and 106%, respectively.
(v) Pharmacokinetic analysis. The total area under the plasma concentration-time curve (AUC), terminal elimination half-life (t 1/2 ), maximum plasma drug concentration (C max ), time to reach C max (T max ), clearance (CL), steady-state volume of distribution (V ss ), and mean residence time (MRT) were calculated using the trapezoidal rule-extrapolation method and noncompartmental analysis (WinNonlin version 5.0; Pharsight, Mountain View, CA). Table 2 ). Pentamidine cured only 1/4 mice at 4 ϫ 5 mg/kg i.p. (23) . In vivo efficacies of 28DAP010 and 19DAP025 were comparable. Cure rates of 3/4 or 2/4 mice were attained at a daily dose of 5 mg/kg i.p. or 1 mg/kg administered on 4 consecutive days. 27DAP060 was slightly more effective than 28DAP010 and 19DAP025. With the low dose of 4 ϫ 0.25 mg/kg i.p., none of the 3 compounds were able to cure any of the mice, and the parasitemia relapses were detected already around 4 days after the last drug administration. 28DAP010 and its dipyridylfuran analogue DB829 showed similar efficacies in the STIB900 acute-stage mouse model (Table 2) .
RESULTS
Acute
CNS T. b. brucei mouse model. The high efficacies in the acute-stage mouse model showed that the compounds merited further testing in the GVR35 CNS mouse model. 28DAP010 was the most potent compound among the three diamidines, curing all infected mice at 10 ϫ 20 mg/kg i.p. (Table 3 ). The high CNS activity is exceptional, having been observed so far with only one other diamidine, DB829 (14) .
The two analogues of 28DAP010 -19DAP025 and 27DAP060 -were both less effective and did not achieve any cures. Additionally, 19DAP025 was toxic and killed most of the mice at the dosages administered. 28DAP010 was also tested at 25 mg/kg for only 5 days and was almost as potent as DB829. This is only a slightly higher total dose than 10 mg/kg i.p. administered for 10 days but was clearly more effective (Table 3) . 28DAP010 was well tolerated in NMRI mice at 5 ϫ 25 mg/kg and 10 ϫ 20 mg/kg i.p., without any overt toxicity observed.
The prodrug DB1244 is a methamidoxime derivative of 28DAP010 (analogous to DB868 being the methamidoxime derivative of DB829). It has been tested orally at 100 mg/kg administered on 5 consecutive days. At identical oral doses, DB1244 was less potent in the CNS mouse model (no cures [ Table 3 ]) than DB868 (5/5 mice cured) (14) . In vitro activity against different trypanosome strains. We analyzed the in vitro activity of 28DAP010 against different trypanosome isolates in the alamarBlue viability assay. As most sleeping sickness patients suffer from T. b. gambiense infections, we tested 28DAP010 against several T. b. gambiense field isolates. The strains and culture conditions were identical to those used to determine the trypanocidal activity of DB829 (23) , so the IC 50 s of 28DAP010 and DB829 can therefore directly be compared. The in vitro IC 50 s of 28DAP010 were higher for all tested T. b. gambiense isolates (IC 50 ϭ 45 to 215 nM [ Fig. 2] ) than for T. b. rhodesiense strain STIB900 (IC 50 ϭ 17 nM) and T. b. brucei strain BS221 (IC 50 ϭ 25 nM). Among the T. b. gambiense strains, there was no clear correlation between isolates from patients suffering from a relapse after melarsoprol treatment (strains whose name includes "R") and reduced potency of 28DAP010 (Fig. 2) , whereas pentamidine appeared to be less active against strains that had been recently isolated (since 2003), which has also previously been shown (23) . 28DAP010 was more active against the four "R" strains (130R, 349R, 40R, and DAL898R) than against the reference melarsoprol-sensitive strain STIB930. ITMAP141267 was the oldest isolate tested in this study (isolated in 1960 from the Democratic Republic of the Congo [DRC]), and it was the strain most sensitive to 28DAP010 and among those most sensitive to pentamidine (Fig. 2) . However, no correlation in reduced trypanocidal activity among T. b. gambiense strains was observed between 28DAP010 and pentamidine (r 2 ϭ 0.019) or with the isolates from melarsoprol-refractory patients.
We additionally studied the dependency of the P2 transporter for the uptake of 28DAP010 into trypanosomes using BS221⌬AT1, a P2 knockout strain (IC 50 ϭ 400 nM), and its corresponding wild type, BS221 (IC 50 ϭ 25 nM), by comparing the IC 50 s determined in the alamarBlue assay. The resistance factor (RF) obtained with 28DAP010 on the P2 knockout strain (RF ϭ 16) was comparable to the RF obtained by DB829 (14) , suggesting that both compounds are taken up primarily by the P2 transporter.
In vivo mouse models with acute-stage infection with different T. b. gambiense isolates. We assessed the efficacy of 28DAP010 in mice against four different T. b. gambiense isolates and compared the activity with that against T. b. rhodesiense STIB900 (Table 4) calculated from the curves for heat flow over time to describe the time course of drug action quantitatively: (i) the onset of drug action, (ii) the time to peak, (iii) the time to kill, and (iv) the growth rate () and hence the level of growth inhibition (1 Ϫ drug / drug free ) (23) .
The time of drug action of 28DAP010 was concentration dependent (Fig. 3) . The higher the concentration, the faster 28DAP010 acted and killed the parasites (in contrast to DB829, with which saturation was observed at Ն2,000 nM [23] ). The onset of drug action on T. b. rhodesiense strain STIB900 ranged from Ͻ4 to 16 h, and the time to kill the parasite culture ranged from 24 to 92 h at concentrations of 20,000 to 20 nM (Table 5 ). At the highest tested drug concentration of 20,000 nM, drug action was so strong that not all parameters could be calculated. Also, the inhibition of the growth rate () was dependent on the drug concentration, ranging from 7% at 2 nM up to Ͼ93% at the highest tested concentration of 20,000 nM.
Drug action of 28DAP010 in vitro was slower for T. b. gambiense strains ITMAP141267 and STIB930 ( Fig. 3 ; Table 5 ) than for T. b. rhodesiense strain STIB900. This is consistent with the reduced activity (higher IC 50 s) of 28DAP010 observed for T. b. gambiense in the alamarBlue assay. Growth of the two T. b. gambiense strains was also slightly slower in drug-free control cultures ( ϭ 0.018 to 0.024 h Ϫ1 , time to peak ϭ 53 to 58 h, and time to overgrowth ϭ 144 to 172 h) than that of T. b. rhodesiense strain STIB900 ( ϭ 0.029 h Ϫ1 , time to peak ϭ 34 h, and time to overgrowth ϭ 111 h) at identical trypanosome inocula of 5 ϫ 10 4 trypanosomes/ml ( Table 5 ). The onset of drug action for the two T. b. gambiense strains ranged from 5 to 30 h and the time to kill ranged from 46 to 126 h (2 to 5 days) at effective concentrations of 200 to 20,000 nM 28DAP010. Also, the inhibition of the growth rate () was dependent on the drug concentration, ranging from 0.6 to 4% at 20 nM up to Ͼ82% at 20,000 nM for both T. b. gambiense strains (Table 5 ).
An inoculum effect is a phenomenon that has previously been observed with several diamidines. We studied the effect of two different initial parasite densities (5 ϫ 10 4 /ml and 1 ϫ 10 4 /ml) on the sensitivity to 28DAP010 by isothermal microcalorimetry (see Fig. S1 in the supplemental material). With an inoculum of 5 ϫ 10 4 /ml, the growth rate of T. b. rhodesiense strain STIB900 was inhibited by 19% at 20 nM and 81% at 200 nM (Table 6 ). Considerably stronger inhibition was observed at the lower inoculum of 1 ϫ 10 4 /ml. The parasite culture was inhibited by 85% at 20 nM and Ͼ98% at 200 nM (Table 6 ; see also Fig. S1 ). In contrast, onset of drug action and time to peak of the heat flow curves remained similar with the different inocula ( Table 6 ). The same phenomenon was observed in the experiments with T. b. gambiense strain STIB930. With an initial inoculum of 5 ϫ 10 4 /ml, parasite growth rate was inhibited by 6% at a drug concentration of 200 nM and by 58% at 2,000 nM. Stronger inhibitions were observed at the lower inoculum, with 51% at 200 nM and Ͼ93% at 2,000 nM ( Table 6 ). The other two parameters, onset of action and time to peak of the heat flow curves, remained again similar at the different inocula. No clear inoculum effect was observed at 2 nM 28DAP010 (see Fig. S1 ).
Diamidines are normally taken up rapidly into trypanosomes, but parasite death is usually delayed. We tested whether continuous drug exposure is required for 28DAP010 to kill the trypanosomes or if an exposure of 24 h is sufficient to kill the parasites at a later time point. Inhibition of trypanosome cultures that were incubated for 24 h with 28DAP010 and then washed was monitored in drug-free culture medium by microcalorimetric analysis. The heat flow of preexposed trypanosome samples in drug-free culture medium was compared with that of parasites continuously exposed to the drug. The wash-out experiments were performed with two strains (STIB900 and STIB930).
The time to peak of the washed, drug-free samples was delayed by 14 to 17 h compared to the drug-free samples that were not washed (Table 6 ; see also Fig. S2 in the supplemental material) . This delay was attributed to loss of some trypanosomes during the washing steps since both samples were set up and run simultaneously. The trypanosome culture was still alive, as seen by heat flow rate above baseline at the 24-h time point, and heat production did increase in the wash-out samples after any drug was removed. This indicates that the cells were still multiplying after the drug preexposure at a 200 or 2,000 nM concentration. However, the cultures in the drug-free medium did die after some time (see Fig.  S2 ). The times to kill after drug wash-out were delayed compared to those with continuous drug exposure (82 versus 37 h) for T. b. rhodesiense strain STIB900 at 200 nM and for T. b. gambiense strain STIB930 (130 versus 85 h) at 2,000 nM (Table 6 ). However, the 24-h exposure was sufficient to kill STIB900 at 200 nM and STIB930 at 2,000 nM at the later time, which confirms that lethal concentrations were taken up within the first 24 h. With lower drug concentrations, a revival of the parasite culture after washout was observed in some cases: with STIB900 at 20 nM and with STIB930 at 200 nM (data not shown).
Pharmacokinetics and brain exposure of 28DAP010 after i.v. and i.p. administration in mice. The mean plasma concentration-time profiles of 28DAP010 were determined after a single i.v. dose of 7.5 mol/kg (2.4 mg/kg) or a single i.p. dose of 65 mol/kg (21 mg/kg) (Fig. 4) . Both profiles exhibited at least a biphasic decline with an initial distribution phase and a terminal elimination phase. Pharmacokinetic outcomes were determined using noncompartmental analysis (Table 7) . Following i.v. administration, the average plasma concentration of 28DAP010 reached 70.2 M about 1 min after i.v. administration, but it quickly decreased, to below 1 M by 2 h postdose and below 0.1 M by 8 h postdose (Fig. 4A) . The steady-state volume of distribution was 15 liters/kg, markedly greater than the physiologic fluid volume. The (5) 27 (1) 20 12 (7) 29 (2) 59 (2) (2) 148 (9) 24 (2) 200 26 (4) 50 (1) 121 (8) 23 (1) 6 2,000 8 (2) 36 (3) 85 (7) 10 (2) 58 1 ϫ 10 4 /ml (low inoculum) None (drug free) 68 (1) 160 (10) 24 (2) 200 27 (3) 52 (5) 100 (11) 12 ( 61 (2) 128 (9) 21 (1) 0 2,000
60 (4) 130 (12) 15 (2) 28 a NM, not measurable. b Inhibition is too strong to recover parameters from every experiment performed accurately. c Only two independent experiments were performed (in triplicate). d Only one independent experiment was performed (in triplicate). e Inhibition was determined as follows: (1 Ϫ drug / drug free ) ϫ 100. average brain concentration of 28DAP010 was 4.2 M at 72 h postdose, approximately 190-fold higher than the corresponding plasma concentration (Table 7) . Following i.p. administration, 28DAP010 was rapidly absorbed into blood circulation, reaching a plasma C max of 69.6 M at 15 min postdose. The average plasma concentration of 28DAP010 decreased below 1 M by 8 h postdose but remained above 0.1 M for at least 72 h after injection (Fig. 4B) . The average brain concentration of 28DAP010 was 9.3 M at 72 h postdose, approximately 69-fold higher than the corresponding plasma concentration ( Table 7) . The nonspecific binding of 28DAP010 to mouse plasma proteins and brain tissues was determined (Table 7) . 28DAP010
showed moderate binding to mouse plasma (f u, plasma ϭ 26.3%) but bound avidly to brain tissues (f u, brain ϭ 0.69%).
Time of drug action in vivo. The time of drug action of 28DAP010 in vivo was determined following a single i.p. dose of 20 mg/kg to mice infected with T. b. rhodesiense strain STIB900 or the T. b. gambiense strains ITMAP141267 and STIB930. The in vivo time to kill (parasite clearance time) of 28DAP010 was determined in the same experiment as the previously reported data for DB829 (23) . Typically, diamidines are rather slow-acting compounds, especially DB829. Therefore, the first blood sample collected was 24 h after treatment. This time point is close to the parasite clearance time of 28DAP010, as in each group one mouse (STIB930 and ITMAP141267) or three of four mice (STIB900 infected) were already parasite free 24 h after drug administration.
The parasite clearance time was, on average, 26 h (24 to 32 h) when mice were infected with the T. b. rhodesiense strain STIB900 (Table 8 ). This is in the range of the in vitro time to kill at 2,000 to 20,000 nM concentrations (24 to 32 h [ Table 5 ]). The time to kill for the T. b. gambiense strain ITMAP141267 was, on average, 42 h (24 to 56 h); that in STIB930-infected mice was 40 h (24 to 48 h) (Table 8) , which is slightly faster than the in vitro time to kill at the two highest concentrations of 2,000 and 20,000 nM (Table 4) .
DISCUSSION
Our studies of the diamidine 28DAP010 and its two analogues 27DAP060 and 19DAP025 showed that they are highly active against African trypanosomes in vivo. In the STIB900 acute-stage mouse model, the mice were cured by a single i.p. dose (Table 2 ) (20) . However, among the three analogues, only 28DAP010 cured mice with second-stage infections in the GVR35 CNS mouse model ( Table 3) .
The availability of more efficacy data for a number of diami- dines makes it possible to consider some structure-activity relationships. 28DAP010 is chemically closely related to DB829 (Fig. 1) . In the present study, 19DAP025 was less CNS potent and more toxic than its diaza analogue 28DAP010 (Table 3) . Most of the infected mice died during or shortly after treatment with 19DAP025 at 5 ϫ 25 mg/kg or 10 ϫ 20 mg/kg i.p. A similar comparison can be made between furamidine and DB829 (14) . 27DAP060, a regioisomer of 28DAP010, was highly active in vivo in the acute-stage mouse model (Table 2 ) but less CNS active than 28DAP010 (Table 3 ). This has been observed in previous experiments with aza analogues of furamidine (DB75) (24) , in which only DB829 cured CNS-infected mice (14) . The two pyridyl nitrogen atoms introduced in DB75 decreased the pK a value of DB829 by only 1 unit, and it was still above physiological pH (36) . The higher BBB penetration can therefore not be attributed to an effect on pK a alone. The identical positions of the nitrogen atoms in the outer pyridine rings in both DB829 and 28DAP010 (Fig. 1) may play a crucial role in CNS potency and in the recognition of the molecules by a presumed transporter protein located at the BBB, which supports the penetration of 28DAP010 and DB829 into the brain. The CNS mouse model results for these two molecules confirm that certain diamidines do indeed have potential for curing not only first-stage but also second-stage HAT by the parenteral administration route.
There is still some interest in the use of prodrugs, particularly because of their potential for oral administration. Since the analogue DB868, the methamidoxime prodrug of DB829, cured mice showing CNS infection after oral administration (14), we analyzed the potency of DB1244, which is a methamidoxime prodrug of 28DAP010, in the GVR35 CNS mouse model at the same dosage. However, DB1244 was much less CNS active than DB868 (Table 3 ) (14), although its acute-stage mouse model activity was similar (Table 2) (14, 20) . Further metabolism and pharmacokinetic studies of DB1244 are needed to explain the observed efficacy difference. When DB868 was tested by the oral route in vervet monkeys with second-stage infections, the therapeutic window was smaller for the prodrug DB868 than for its active diamidine DB829 (18) . Measurement of the efficacy of 28DAP010 in the second-stage vervet monkey model will be needed for comparison with DB829.
Our greatest concern was to test the susceptibilities of different T. b. gambiense isolates to 28DAP010, as Ͼ98% of all HAT cases are due T. b. gambiense infections (2) . Most of our strains were isolated from patients from the Democratic Republic of the Congo (DRC), the country harboring most HAT patients (1). We observed considerable reduction in the in vitro activity of 28DAP010 against the different T. b. gambiense strains compared to T. b. rhodesiense and T. b. brucei strains. This phenomenon has been observed previously with DB829 (against all tested T. b. gambiense isolates) and with pentamidine against recent isolates (K03048, 40R, 45R, 130R, and 349R) that were derived from patients within the last 10 years (23). However, our in vivo experiments with T. b. gambiense infections with four different isolates (ITMAP141267, STIB930, 130R, and 45R) were encouraging. 28DAP010 proved to be highly active against T. b. gambiense as well as T. b. rhodesiense isolates. The T. b. gambiense-infected mice were cured at doses comparable to, or even lower than, those used for mice infected with T. b. rhodesiense STIB900 ( Table 4 ). The reduced in vitro activities of 28DAP010 and DB829 may be the result of factors that do not influence activity in vivo. They could be due to the slower growth of T. b. gambiense isolates or be the result of different culture conditions leading, for example, to a downregulation of a diamidine uptake transporter(s) (37) and thus to a reduced susceptibility of the T. b. gambiense isolates in vitro (23) .
Cross-resistance between pentamidine and melamine-based arsenicals such as melarsoprol is a well-known phenomenon (38) (39) (40) involving the P2 transporter (41, 42) . Therefore, we were concerned about a possible cross-resistance between 28DAP010 and these drugs or the possible development of more resistant trypanosome strains. Tests using a P2 knockout (KO) T. brucei strain indicated that the uptake of 28DAP010 is dependent on the P2 transporter. We observed a resistance factor (IC 50 P2-KO /IC 50 wild type ) of 16, which was similar to that for DB829 and diminazene in the 72-h alamarBlue assay (14) . Recently another transporter, aquaporin 2 (AQP2), was identified which is also involved in drug uptake and the development of resistance to pentamidine and melarsoprol (40, 43, 44) . However, cross-resistance seems to be limited to the two diamidines pentamidine and 28DAP010, as the IC 50 s of the two diamidines for different T. b. gambiense field isolates do not correlate (r 2 ϭ 0.019) (Fig. 2) . A similar effect was observed between pentamidine and diminazene (44) . Analysis of T. b. gambiense field isolates with reduced susceptibility to pentamidine did reveal rearrangements of the TbAQP2/TbAQP3 locus accompanied by TbAQP2 gene loss (44) . The mutant T. b. gambiense field isolates were less susceptible to pentamidine and melarsoprol but still susceptible to diminazene (44) and DB829 (23) and, as can be seen in Fig. 2 , also to 28DAP010. Additionally, 28DAP010 was able to cure mice that were infected with recent T. b. gambiense isolates that were less susceptible to pentamidine in vitro (Table 4) . Lack of AQP2 dependency for uptake of 28DAP010 and DB829 would explain why the recent T. b. gambiense isolates that were less susceptible to pentamidine were still sensitive to 28DAP010 and DB829.
An understanding of the pharmacokinetics and pharmacodynamics of drugs is necessary to develop effective treatment schedules. The time of drug action on trypanosomes can be determined in vitro using isothermal microcalorimetry (21) . This method is based on the heat production of metabolically active parasites and thus allows studying the growth of cultures in the presence and absence of drugs (21, 23) . It is simple to use and offers constant monitoring of a parasite population on a real-time basis (21) .We analyzed the time of drug action of 28DAP010 at different concentrations on 3 different trypanosome strains. The time course of drug action was concentration dependent. No saturation could be observed with 28DAP010, whereas in experiments with DB829, saturation was found above 2,000 nM (23) . This was probably due to saturation of the P2 transporter with DB829 (23, 37) . It is possible that 28DAP010 is taken up by an additional high-capacity, low-affinity transporter at high drug concentrations, leading to a stronger drug action at concentrations above 2,000 nM.
We studied the inoculum effect of 28DAP010 by using identical drug concentrations but different initial parasite densities (inocula), 1 ϫ 10 4 /ml and 5 ϫ 10 4 /ml (see Fig. S1 in the supplemental material). We observed a strong inoculum effect on the growth rate () and on the time to kill. However, the onset of drug action and the time to peak were less affected at the different trypanosome starting densities at identical drug concentrations, as can be observed at 20 and 200 nM concentrations with STIB900 or at 200 and 2,000 nM concentrations with STIB930 (Table 6 ). This indi-cates that the drug action starts almost concurrently at the different starting densities using the same drug concentration. This phenomenon has been previously observed with DB829 and pentamidine in microcalorimetric studies (23) . The major reason for the inoculum effect in vitro seems to be the concurrent onset of drug action, which appears at a much lower trypanosome density at the lower inoculum. Therefore, the inhibition of these compounds is more pronounced than for the drug-free control samples at the lower inoculum than at the higher inoculum.
The time taken to kill parasites is an important parameter to measure treatment efficacy. It has been shown that several diamidines (such as pentamidine, DB75, and DB829) are rapidly taken up by African trypanosomes; however, trypanosome death occurred much later (9, 23, 45, 46) . We studied the drug action at effective concentrations (200 nM for STIB900 and 2,000 nM for STIB930) for an exposure time of 24 h, after which the drug was washed out (see Fig. S2 in the supplemental material). Growth was followed by isothermal microcalorimetry. After the drug had been washed out from the trypanosome culture, the parasites seemed to grow for at least one more day (see time to peak in Table 6 ). The trypanosomes were finally killed as a consequence of the 24-h drug exposure, but death occurred almost 2 days later than in continuously exposed trypanosomes (Table 6 ; see also Fig. S2 ). Microcalorimetric studies with multiple concentrations of 28DAP010 and multiple time points would be needed to examine this phenomenon in detail, but this was beyond the scope of this study. The performed wash-out experiments suggest that the high maximum drug concentration in plasma (C max ) after i.p. administration (Table 7) (Tables 2 and 4) is not surprising considering the high C max combined with the long half-life of 28DAP010.
28DAP010 showed a high brain-to-plasma concentration (B/P) ratio at 72 h postdose (Table 7) , suggesting good CNS penetration. The high B/P ratio appears to be largely driven by the more extensive binding of 28DAP010 to brain tissue than to plasma (f u, plasma /f u, brain ). However, it has been previously observed using fluorescence microscopy that DB75 did not distribute into brain parenchyma but sequestered within endothelial cells lining the BBB and blood-cerebrospinal fluid barrier. It is unknown whether 28DAP010 was also sequestered within the endothelial cells or distributed more extensively into brain parenchyma. Nonetheless, the observed high B/P ratio and efficacy in the CNS T. b. brucei mouse model support 28DAP010 as a CNSactive trypanocide.
The speed at which drugs act is of varying clinical importance. Fast elimination of the parasite is not as vital for HAT patients as it is for patients infected with some other parasites, like malaria parasites, which cause much more rapid death. However, fast-acting drugs are of advantage to minimize the risk of resistant parasite selection in the patient and to reduce the hospitalization time. In vitro as well as in vivo, 28DAP010 was faster acting than DB829. However, a short exposure to 28DAP010 or to DB829 (23) was sufficient to kill the trypanosomes in a delayed manner (Table 6 ). High drug levels therefore do not need to be maintained over the entire parasite clearance time in vivo.
More problematic than a relatively slow speed of action are undesirable side effects such as hepatotoxicity or nephrotoxicity. Such effects have been observed for pentamidine (47) and DB289 (pafuramidine) (15, 16, 48) , and the nephrotoxicity of pafuramidine actually led to the termination of the clinical studies (16) . It is encouraging that studies with rats and mice indicate that nephrotoxicity is not clearly class related (49) . DB829 (resulting from DB868 administration) accumulated less in liver and kidneys than did DB75 (after pafuramidine administration) (16) . The toxicity profile of 28DAP010 may also differ from that observed for pafuramidine.
Second-stage efficacy of DB829 has been demonstrated in the mouse (14) and monkey (18) models. In the present study, 28DAP010 revealed similar efficacies in mouse models. Both molecules are able to cure both disease stages and infections with both studied subspecies, T. b. gambiense and T. b. rhodesiense, at low and tolerated doses. Extensive toxicity studies of 28DAP010 and DB829 side by side are still needed. Drug tolerability will be an important criterion for choosing the better of these two diamidines for further drug development.
There is a continuing discussion about the relative advantages and disadvantages of prodrugs and intrinsically active compounds. The use of an orally active prodrug to cure second-stage HAT could be helpful in resource-poor settings. However, parenteral administration also has advantages. The use of an active diamidine will simplify the pharmacokinetic and toxicity analyses that will be needed if the drug is to be used, and treatment with one of the backup compounds, 28DAP010 or DB829, could be short and simple. Treatment duration of 5 days or less for second stage could well be feasible and could be tested for further development for HAT on the basis of the favorable pharmacokinetics after parenteral administration.
A sustained drug development pipeline will increase the chance of getting a new and improved treatment into the market (19) . This will help to control, and eventually to eliminate, the disease (50, 51) . With 28DAP010, we have found a new promising backup diamidine as a preclinical candidate for the treatment of first-and second-stage African sleeping sickness.
